Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers.

Haixiang QinYingqiang LuLin DuJingyan ShiHaoli YinBo JiangWei ChenWenli DiaoMeng DingWenmin CaoXuefeng QiuXiaozhi ZhaoHong-Qian Guo

Published in: Cancer cell international (2022)

LMNB1 is a biomarker of CD4+ Th2 cell infiltration and DNA homologous recombination repair in human cancers. Blockage of LMNB1 combined with PARP inhibitor treatment could be a promising therapeutic strategy for patients with cancers.

Keyphrases

dna repair
dna damage
endothelial cells
induced pluripotent stem cells
pluripotent stem cells
papillary thyroid
single cell
squamous cell carcinoma
childhood cancer
cell therapy
mesenchymal stem cells
dna methylation
single molecule
bone marrow
combination therapy
nucleic acid